By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its second-quarter revenues climbed 11 percent due primarily to increased sales and marketing efforts and improved physician acceptance of its products.

The Salt Lake City-based firm brought in total revenues of $92.8 million for the three-month period ended Dec. 31, compared with $84 million for the second quarter of 2009. Analysts, on average, had expected revenues of $91.6 million for Q2 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.